NCT07791199Not yet recruitingPhase 3
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
A Continuation Protocol for Deucravacitinib in Adult Patients With Systemic Lupus Erythematosus (SLE) or Sjögren's Disease (SjD) and Pediatric Patients With Psoriasis (PsO) or Psoriatic Arthritis (PsA) Who Have Completed Parent Studies
Source: ClinicalTrials.gov · Last updated 3 Sept 2026
Brief summary (registry, in English)
This study is designed to provide treatment with deucravacitinib for participants with SLE/SjD (Systemic Lupus Erythematosus/Sjögren's Disease) and pediatric participants with PsO/PsA (Psoriasis/Psoriatic Arthritis) who have completed their qualified parent studies and/or long-term extension if applicable.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 2300 (estimated)
- First submitted
- 25 Aug 2026
- Start date
- 31 Dec 2026
- Primary completion date
- 31 Oct 2030
- Lead sponsor
- Bristol-Myers Squibb
- NCT number
- NCT07791199
- EudraCT number
- 2026-527576-84
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 2300
- From 31 Dec 2026 to the primary completion date, 31 Oct 2030
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Participants must not have any disease or medical condition that, in the opinion of the physician, would make them unsuitable for this protocol, would interfere with the interpretation of their safety or considered unsuitable by the physician for any other reason.
- Other protocol-defined inclusion/exclusion criteria apply.
Who the study is looking for
- Participants must have completed qualifying parent study through the protocol required treatment period. Qualifying studies include IM011-246, IM011-247, IM011-1069, IM011-126, IM011-1128, and IM011-1071.
Age in the registry: 4 years to 75 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.